Gastric and Esophageal
- Colon, Esophagus, Liver, Lung, Other Digestive Organ, Phase I, StomachA Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors
- EsophagusA Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-PositivePrincipal Investigator: Raghav Sundar
- Cervix, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Lung, Phase I, Rectum, Small Intestine, Stomach, ThyroidA Phase 1, Open-label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB168 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Malignancies
- Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, Skin, Urinary BladderAn Open-Label, Phase 1 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AB821 in Adult Participants With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
- Colon, Esophagus, Liver, PancreasA Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal CancersPrincipal Investigator: Raghav Sundar